Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

FDA warns of lung inflammation for CDK4/6 drugs
FDA issued a warning Friday that marketed CDK4/6 breast cancer drugs have been associated with a severe but rare risk of lung

Read the full 296 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE